Table 1.
Characteristics of patients at the start of sodium–glucose cotransporter 2 inhibitors administration, and data of medication at the start and after 2 years of sodium–glucose cotransporter 2 inhibitors administration
| At the start of SGLT2 inhibitors | ||
|---|---|---|
| Age, years (n = 85) | 72.0 ± 9.4 | |
| Male, % (n = 51) | 60.0 | |
| Duration of diabetes, years (n = 85) | 18.4 ± 9.4 | |
| Bodyweight, kg (n = 85) | 71.3 ± 15.3 | |
| Body mass index, kg/m2 (n = 85) | 27.7 ± 5.3 | |
| Systolic BP, mmHg (n = 83) | 130.0 ± 17.0 | |
| Diastolic BP, mmHg (n = 83) | 70.0 ± 12.0 | |
| eGFR, mL/min/1.73 m2 (n = 85) | 47.1 ± 9.7 | |
| At the start of SGLT2is | After 2 years of SGLT2is | |
| Antidiabetic drugs (%) | ||
| Insulin | 41.2 (n = 35) | 38.8 (n = 33) |
| Sulfonyl urea | 25.9 (n = 22) | 30.1 (n = 26) |
| DPP‐4 inhibitor | 65.9 (n = 56) | 55.3 (n = 47) |
| Metformin | 68.2 (n = 58) | 69.4 (n = 59) |
| α‐Glucosidase inhibitor | 12.9 (n = 11) | 15.3 (n = 13) |
| Thiazolidine | 4.7 (n = 4) | 3.5 (n = 3) |
| GLP‐1 receptor agonist | 3.5 (n = 3) | 16.4 (n = 14) |
| SGLT2 inhibitors (%) | ||
| Empagliflozin | 40.0 (n = 34) | 38.8 (n = 33) |
| Ipragliflozin | 15.3 (n = 13) | 7.0 (n = 6) |
| Dapagliflozin | 15.3 (n = 13) | 18.8 (n = 16) |
| Luseogliflozin | 15.3 (n = 13) | 12.9 (n = 11) |
| Canagliflozin | 11.8 (n = 10) | 22.4 (n = 19) |
| Tofogliflozin | 2.4 (n = 2) | 0 (n = 0) |
| Other drugs (%) | ||
| ARB | 51.8 (n = 44) | 48.2 (n = 41) |
| ACEI | 20.0 (n = 17) | 21.1 (n = 18) |
| ARB + ACEI | 2.4 (n = 2) | 1.2 (n = 1) |
| Spironolactone | 12.9 (n = 11) | 15.3 (n = 13) |
| RAAS inhibitors | 69.4 (n = 59) | 68.2 (n = 58) |
| Calcium blocker | 56.5 (n = 48) | 55.3 (n = 47) |
| Diuretics | 32.9 (n = 28) | 24.7 (n = 21) |
| Statin | 64.0 (n = 54) | 67.1 (n = 57) |
| Fibrates | 10.6 (n = 9) | 11.8 (n = 10) |
Data presented as mean ± standard deviation. ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BP, blood pressure; DPP‐4, dipeptidyl peptidase‐4 inhibitors; eGFR, estimated glomerular filtration rate; GLP‐1, glucagon‐like peptide‐1; RAAS, renin–angiotensin–aldosterone system; SGLT2, sodium–glucose cotransporter 2.